AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05471531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine
Description: Quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine were manufactured by Sinovac Biotech Co., Ltd.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0.
Study NCT05471531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Separate vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine
Description: Quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine were manufactured by Sinovac Biotech Co., Ltd.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0 and one dose of 23-valent pneumococcal polysaccharide vaccine on day 28 in subgroup 1,and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of quadrivalent influenza vaccine on day 28 in subgroup 2.
Study NCT05768165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Description: Twelve weeks of supervised high intensity aerobic and resistance exercise including two sessions/week, one additional session of the patient´s own choice, non-supervised. The target of the high intensity intervals (HIIT) is 90%-95% of maximum heart rate alternated with recovery phases at 70% of maximal heart rate. The resistance exercise session of large muscle groups: 8-10 repetitions, 2-3 sets.~Exercise guidance follows principles of self-efficacy and person-centeredness.
Study NCT04659122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AT-100
Description: reconstituted AT-100 for intratracheal administration
Study NCT05167890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coffee
Description: Coffee 3 times per day
Study NCT05167890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Orange juice
Description: Orange juice 3 times per day
Study NCT04703998 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic rotator cuff repair
Description: A double-row rotator cuff repair will be performed.
Study NCT04703998 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair
Description: A double-row rotator cuff repair will be performed.
Study NCT04703998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: A single dose of 10 ml of autologous platelet rich plasma at the bone-tendon interfase will be administered.
Study NCT05173337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Description: Nefopam 20 mg is mixed to 100 mL of normal saline, and is infused intravenously over 15 minutes.~20 mg of nefopam is administered intravenously for two times, after induction and at the end of surgery.
Study NCT04683003 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-755
Description: TAK-755 IV infusion
Study NCT04835792 — intervention group
Intervention type: OTHER
Intervention: Stool and blood collection
Description: One-time stool and blood collection
Study NCT04693039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenlarmide
Description: Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.
Study NCT04693039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.
Study NCT05555576 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 1000 mg vitamin C taken orally twice a day (one in the morning and one in the evening) for a 14-day period after ED discharge for the treatment arm
Study NCT05555576 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken orally twice a day (one in the morning and one in the evening) for a 14-day period after ED discharge for the treatment arm
Study NCT05103800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: invasive interventions
Description: listening the white noise during the invasive interventions
Study NCT06235320 — intervention group
Intervention type: OTHER
Intervention: routine clinical treatment of pain with paracetamol or ibuprofen
Description: No intervention beside clinical routine management
Study NCT04687189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound performed by a woman herself (with HCP supervision via telemedicine)
Description: Imaging performed by woman on herself with remote healthcare professional (HCP) supervision compared to images taken when same ultrasound is administered in person by HCP. The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
Study NCT05184387 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: Collection of blood samples and completion of an electronic Diary (eDiary)
Study NCT05444270 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard salvage therapy
Description: Subjects will continue to receive current salvage treatment suitable for subjects at the discretion of their doctor, considering the location and size of recurrence, and the patient's comorbidities.
Study NCT05444270 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard salvage therapy + SABR
Description: Subjects receive SABR for lesions found in imaging studies. Before or After SABR, standard salvage treatment continues as planned at the discretion of the doctor.
Study NCT04997772 — intervention group
Intervention type: DEVICE
Intervention: Digital Gaucher Platform
Description: Digital platform specified for Gaucher patients.
Study NCT05241353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced Frequency Self-Monitoring
Description: Participants will be asked to record only a subset of daily eating throughout the intervention, with the prescription for self-monitoring individually tailored at baseline dependent on participants' self-reported eating patterns.
Study NCT05241353 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Full-Frequency Self-Monitoring
Description: Participants will be asked to record all contents of their diet throughout the intervention.
Study NCT05241353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Behavioral Treatment
Description: Participants will receive four individual coaching calls over 12 weeks. During coaching calls, participants will receive guidance on lowering calorie intake, increasing physical activity and use of specific behavioral strategies to increase the probability of success with weight loss.
Study NCT05241353 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Treatment
Description: Participants will receive four individual coaching calls over 12 weeks. During coaching calls, participants will receive guidance on lowering calorie intake, increasing physical activity and use of specific behavioral strategies to increase the probability of success with weight loss.
Study NCT06266208 — intervention group
Intervention type: PROCEDURE
Intervention: Exostectomy
Description: Patients diagnosed with dorsal osteophyte and experiencing pain were advised to proceed with osteophyte removal surgery during their initial visit.The surgical procedure, following protocol occurred during the second visit and involved the following steps: a 2-4 mm incision using a Beaver-64-MIS scalpel on the distal surface wall of the toe, parallel to its longitudinal axis, followed by careful osteophyte drilling; precise delineation of the osteophyte contour using a blunt elevator to prevent nailbed damage; resection executed through medial and lateral movements facilitated by a mini-Shannon drill; and finally, pressure application with a surgical spoon to extract the bone paste resulting from the drilling process.
Study NCT06266208 — intervention group
Intervention type: PROCEDURE
Intervention: Cut fingernail
Description: Patients diagnosed with dorsal osteophyte and experiencing pain underwent nail cut fingernail
Study NCT04956705 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium
Description: Either as tablets, droplets or sprays. Preferably daily doses of 20 µg of vitamin D and 800-1000 mg of calcium as recommended.
Study NCT05774288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cera™ patent foramen ovale occluders
Description: Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Cera™ patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
Study NCT05774288 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Another patent foramen ovale occluders
Description: Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Another patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
Study NCT06155708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone
Description: - Ketone monoester supplement in the form of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.45ml/kg body weight) ingested with water and vanilla-flavored stevia in a total volume of 100 ml.
Study NCT06155708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 100 ml water combined with 10ml bitter flavor and vanilla-flavored stevia
Study NCT06081218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: activity test
Description: Over 2 weeks, participants have to do a maximal progressive exercise and a 30 min constant exercise at 50% of maximal aerobic power
Study NCT06081218 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: activity test
Description: Over 2 weeks, participants have to do a maximal progressive exercise and a 30 min constant exercise at 50% of maximal aerobic power
Study NCT05030948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tiempo Juntos Intervention
Description: If assigned to this group, participants will take part in weekly 1-hour group sessions twice a week for 3 months. The sessions will be with a trained Community Health Worker that will involve group (5-6 participants) moderate-intensity walking. Upon completing the 3 months of physical activity sessions, for the next 3 months, they will receive motivational booster sessions delivered every other week via phone calls/text messaging.
Study NCT06429605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: In addition to our standard clinical protocol, study patients were administered 60 mg oral duloxetine 2 hours before surgery and 24 hours after surgery
Study NCT06360289 — intervention group
Intervention type: OTHER
Intervention: Standard of Care
Description: This is an observational study. No study drug will be administered as a part of the study, participants will be treated according to the decision of the treating physician.
Study NCT06422923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NRTX-1001
Description: Biological: NRTX-1001 is an inhibitory neural cell therapy investigational product. It is derived from a human stem cell line that has been converted into high-purity inhibitory interneurons that produce GABA. NRTX-1001 is intended to persist long-term and not require repeated administration.
Study NCT05935358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nuwiq
Description: Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).
Study NCT06777108 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inorganic Nitrate
Description: The intervention evaluates the single and 1/2-dose pharmacokinetics of a plant-based bioequivalent inorganic nitrate (NO3-) complex with vitamins, antioxidantsand phytophenol rich food extracts.
Study NCT05588479 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract
Description: Two capsules of pomegranate extract (740 mg) will be taken daily at any time of the day for a period of 12 weeks.
Study NCT05588479 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: One capsule of containing no pomegranate extract will be taken daily at any time of the day for a period of 12 weeks.
Study NCT06296173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protective open-lung extubation
Description: Emergence using 50% FiO2, semi-sitting position with pressure support ventilation and preserved PEEP
Study NCT06296173 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional extubation
Description: Emergence using 100% FiO2, dorsal decubitus position with assistance or manual bag ventilation without PEEP
Study NCT04163614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IBPS-Guided Ultrafiltration
Description: Each month, the study investigator will review the average intradialytic blood pressure slope from the prior two weeks. A prespecified algorithm will be used to prescribe additional fluid removal/weight reduction based on this slope.
Study NCT05051436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 MG
Description: Mirabegron 50 mg/day will be administered for 14 weeks.
Study NCT05051436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 MG
Description: Tadalafil 10 mg/day will be administered for 14 weeks after baseline procedures.
Study NCT05051436 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered for 14 weeks after baseline procedures.
Study NCT05331521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CETEG
Description: At progression, patients without prior radiotherapy will undergo radiotherapy and PCV as an adjunct chemotherapy if bone marrow reserve allows in the experimental arm.
Study NCT05331521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCV
Description: In the comparator arm there is the option for second radiotherapy or even reuse of the full radiochemotherapy regimen as it had been given at diagnosis (BIC).
Study NCT05331521 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: RT
Description: Radiotherapy at 50.4/54 Gy in 1.8 Gy fractions for grade 2 and 59.4 Gy in 1.8 Gy fractions for grade 3 gliomas
Study NCT06456203 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: AI
Description: Artificial intelligence triage and reporting system
Study NCT05842174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine to be administered intra-arterially at time of transarterial embolization as well as orally for 6 weeks following the procedure
Study NCT05842174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipiodol
Description: Lipiodol is an FDA-approved drug delivered agent and embolic which is administered as standard of care for transarterial embolization for hepatocellular carcinoma. Lipiodol will be administered intra-arterially in both arms at the time of procedure.
Study NCT05842174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipiodol
Description: Lipiodol is an FDA-approved drug delivered agent and embolic which is administered as standard of care for transarterial embolization for hepatocellular carcinoma. Lipiodol will be administered intra-arterially in both arms at the time of procedure.
Study NCT05842174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally for 6 weeks following the procedure to patients in arm 2
Study NCT06781736 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Talking Circle intervention
Description: Talking Circle intervention
Study NCT06786104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIDEO-PEDS
Description: Following enrollment, parents will receive a link to view the refined video decision aid that is designed to prompt parents to think about their goals of care for their child with cancer, and then to react by engaging in communication with a trained member of the research team called the Navigator and eventually their clinical team over the course of the 9-month study duration.
Study NCT06786104 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: VIDEO-PEDS pilot
Description: This is the 3-month pilot version of the intervention, which will be further developed for the eventual RWCT.
Study NCT06786104 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Focus Group
Description: Parents will view the Video aid and provide fascilitated feedback in an audio-recorded virtual group setting.
Study NCT06782529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide Low Dose
Description: Subjects will receive a reduced dose of 20mg of triamcinolone acetonide.~Total injection volume of 5ml, consisting of:~* 0.5ml triamcinolone acetonide (20mg)~* 4.5ml lidocaine (45mg)
Study NCT06782529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide Standard Dose
Description: Subjects will receive the standard of care dose of 40mg triamcinolone acetonide~Total injection volume of 5ml, consisting of:~* 1ml triamcinolone acetonide (40mg)~* 4ml lidocaine (40mg)
Study NCT06786780 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug: Cisplatin
Description: Organoids were constructed prior to simultaneous radiochemical therapy
Study NCT06783894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise (elliptical training)
Description: twenty irritable bowel syndrome men with sexual dysfunction ( weak erection of penis or erectile dysfunction) will perform ellpitical physical activity (40 minutes on elliptical trainer three times weekly. the duration of physical activity will be 12 weeks.
Study NCT06785831 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium
Description: Participants will once daily consume predefined amount of psyllium, corresponding to 3 g of dietary fibre, for 28 days.
Study NCT06785831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sauerkraut
Description: Participants will once daily consume predefined amount of sauerkraut, corresponding to 3 g of dietary fibre, for 28 days.
Study NCT06785831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh apples
Description: Participants will once daily consume predefined amount of fresh apples, corresponding to 3 g of dietary fibre, for 28 days.
Study NCT06785831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dried apples
Description: Participants will once daily consume predefined amount of dried apples, corresponding to 3 g of dietary fibre, for 28 days.
Study NCT06783166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin 10 mg is a medication classified as a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
Study NCT06783166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide 500mg
Description: Acetazolamide 500 mg is a medication classified as a carbonic anhydrase inhibitor.
Study NCT06783530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Splint Therapy with Enhanced Doctor-Patient Communication
Description: A structured communication protocol aimed at improving doctor-patient interaction and treatment adherence.
Study NCT06783530 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splint Therapy
Description: A custom-fitted occlusal splint designed to alleviate symptoms of temporomandibular disorders (TMD).
Study NCT06785935 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle knife
Description: ultrasonography-guided percutaneous A1 pulley release using a needle knife
Study NCT06785935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid: Betamethasone
Description: ultrasonography-guided corticosteroid injection under the A1 pulley
Study NCT06786949 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: All cases and controls will be contacted by telephone or e-mail and invited to participate in the study. Female workers who decide to join the study will be asked to go to their company's occupational health clinic where they will undergo administration of a questionnaire to investigate possible known and unknown risk factors for breast cancer
Study NCT06786949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples for biomarker measurement
Description: Women who give consent to undergo this phase of the study will be called back to the center and will be asked to provide a blood sample
Study NCT06784999 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sufentanil
Description: 1. Intravenous sufentanil starting at a dose of 0.5 mcg/kg/min hr ideal body weight (IBW) at the beginning of the case, prior to surgical incision, with a discontinuation of the infusion when the surgical microscope is removed from the patient field and the closure of the incision(s) begins. (n=64)
Study NCT06784999 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: methadone
Description: 2. Intravenous methadone of 0.2 mg/kg IBW up to a maximum dose of 20mg, rounded to the nearest milligram. The methadone will be given at the beginning of the case, prior to surgical incision. n=64)
Study NCT06782685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposoma
Description: Exploration started with 50mg/m\^2 dose, preset 50mg/m\^2, 60mg/m\^2, 2 dose groups, IV infusion 90min, d1